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Introduction to reporter genes and molecular imaging
Novel medical therapies, diagnostics, and cures previously not
imagined are anticipated to emerge from the refined map of the
human genome. The application of genomics has provided new
means for recognizing the molecular basis of numerous dis-
eases and identifying novel drug targets for pharmacological
intervention and diagnostics. Routinely used methodologies to
study biological processes are based on destructive sampling
of biological material, thus allowing the researcher to witness
only a static snapshot taken at the respective experimental end-
point. Introduction of green fluorescent protein (GFP) and its
analogs and the evolution of live-cell fluorescence microscopy
revolutionized our understanding of many processes at the
molecular and cellular levels. With the development of suitable
probes and instrumentation for functional imaging in vivo, our
ability to identify and measure biological processes in real time
has progressively extended to the whole organism.This new set
of molecular probes, detection technologies, and imaging
strategies, collectively termed molecular imaging (Sharma et
al., 2002; Weissleder, 2002; Blasberg and Tjuvajev, 2003;
Contag and Bachmann, 2002; Gelovani Tjuvajev and Blasberg,
2003; Herschman, 2003; Massoud and Gambhir, 2003;
Piwnica-Worms et al., 2004), is providing biologists with exciting
new opportunities to perform noninvasive and longitudinal stud-
ies of dynamic biological processes in intact cells and living ani-
mals. In the last five years, a series of groundbreaking studies
have demonstrated that molecular imaging is a powerful tool
that enables visualization of gene expression, biochemical
reactions, signal transduction, and regulatory pathways in
whole organisms in vivo. The ability to image fundamental
processes such as transcriptional regulation, signal transduc-
tion, protein-protein interactions, oncogenic transformation, cell
trafficking, and targeted drug action provides ample reason to
incorporate imaging reporters into cancer research.
Imaging reagents can comprise injectable radiopharmaceu-
ticals and contrast agents, with or without activation strategies
(Bremer et al., 2001; Louie et al., 2000; Ntziachristos et al.,
2002; Piwnica-Worms et al., 2004), or genetically encoded
reporters (Blasberg and Tjuvajev, 2003; Gelovani Tjuvajev and
Blasberg, 2003; Sharma et al., 2002). Both types of reagents
are useful in biological studies, but injectable agents have the
potential to directly translate to the clinic. Except in the context
of gene therapy, genetically encoded reporters are less likely to
be used in humans, but possess a fundamental advantage in
basic research, in that once validated, a genetically encoded
reporter can theoretically be cloned into a variety of vectors,
and a broad array of regulatory pathways can be interrogated
with the same validated reporter. For radiopharmaceuticals, this
eliminates constraints inherent to traditional routes of synthesiz-
ing, labeling, and validating a new and different radioligand for
every new receptor or protein of interest. Genetically encoded
imaging reporters, representing the focus of this review, also
provide the potential for a stable source of signal enabling longi-
tudinal studies in living organisms with high temporal and, in
some cases, high spatial resolution.
Regardless of the examined process, any strategy for imag-
ing genetically encoded reporters is comprised of three major
components: (1) a reporter gene that generates an imagable sig-
nal, (2) a regulatory element governing the activity of the
reporter gene and therefore generating contrast (e.g., a constitu-
tive or inducible promoter, an upstream cis-regulatory sequence,
or a polypeptide fused in frame with the reporter gene and there-
by posttranscriptionally regulating its activation), and (3) a detec-
tion device able to noninvasively sense and quantify the signal
produced by the reporter gene within the intact cell or organism.
Genetically encoded reporters can produce signal (1) intrinsical-
ly by the reporter (e.g., fluorescent proteins), (2) through enzy-
matic activation of an inactive substrate by the reporter (e.g.,
firefly luciferase that catalyses the light-producing reaction from
the substrate D luciferin in the presence of O2 and Mg2+-ATP), (3)
by enzymatic modification of an active (e.g., radiolabeled) sub-
strate producing selective retention in reporter cells (e.g., selec-
tive retention of [18F]FHBG by herpes simplex virus 1 thymidine
kinase [HSV1-TK]; Luker et al., 2002b), or (4) by direct binding or
import of an active substrate (e.g., binding of radiolabeled
somatostatin to somatostatin receptor type 2 [SSTR2]-express-
ing cells; Rogers et al., 2000). Table 1 lists common reporter
genes used in molecular imaging.
Specialized detection devices for imaging small animals
more or less coevolved during the late 1990s. The imaging
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modalities can be divided into three major groups: (1) nuclear
imaging (e.g., single photon emission computed tomography
[SPECT] or positron emission tomography [PET]), (2) magnetic
resonance imaging (MRI), and (3) optical imaging (e.g., fluores-
cence imaging and bioluminescence imaging). MicroPET,
microSPECT, and cooled charge-coupled device (CCD) cam-
eras for low light bioluminescent imaging of small animals are
becoming widely available (Massoud and Gambhir, 2003;
Piwnica-Worms et al., 2004). In addition, introduction of red-
shifted fluorescence proteins (Campbell et al., 2002; Shaner et
al., 2004; Wang et al., 2004) and injectable near-infrared (NIR)
fluorescent probes (Bremer et al., 2001; Weissleder et al.,
1999), progression in development of highly sensitive photon
detection devices and in vivo microscopy (confocal and multi-
photon; Zipfel et al., 2003), and advances in mathematical mod-
eling of photon propagation in tissues (Weissleder and
Ntziachristos, 2003) have yielded innovative macro- and micro-
scopic fluorescence imaging modalities such as fluorescence
tomography (Ntziachristos et al., 2002), spectrally resolved
whole body fluorescence imaging (Levenson and Mansfield,
2004; Mansfield and Levenson, 2004), and intravital multipho-
ton imaging (Zipfel et al., 2003).
Although exciting advances are emerging, fluorescence
imaging still suffers from pitfalls such as the inability to quantify
photon output, high autofluorescence in the blue-green window
resulting in low signal-to-noise ratios, fluorophore photo-bleach-
ing, and high levels of photon attenuation and scattering in living
tissues. However, imaging of fluorescence proteins (preferably
monomeric red-shifted reporters) has an important advantage
over other imaging modalities with genetically encoded
reporters, i.e., no substrate is required, which uncouples read-
out from substrate pharmacokinetics and thereby enables true
real-time imaging. In addition, subcellular localization is possi-
ble by correlative microscopic analysis.
Nuclear imaging (SPECT and PET) is highly sensitive
(detecting fmole levels of probe), quantitative, and inherently
tomographic. However, nuclear imaging demands sophisticated
instrumentation, committed personnel, readily available in-
house production of radiopharmaceuticals, and stringent
dependency on tracer pharmacokinetics. Bioluminescence
imaging of luciferase reporters provides a relatively simple,
robust, cost-effective, and extremely sensitive means to image
fundamental biological processes in vivo due to exceptionally
high signal-to-noise levels. Nevertheless, bioluminescence
remains dependent on substrate pharmacokinetics, and in gen-
eral offers only planar imaging datasets, therefore imposing
some positional uncertainty of the attained signal. There are
many luciferases with matching substrates available. However,
most are blue/green and therefore are less suitable for deep tis-
sue imaging. The luciferases that have been found to be most
useful for molecular imaging are firefly (Photinus pyralis)
luciferase, Renilla luciferase, green or red click beetle
(Pyrophorus plagiophthalamus) luciferases, and Gaussia
luciferase (Contag and Bachmann, 2002; Tannous et al., 2004;
Zhao et al., 2004). However, both Renilla and Gaussia luciferas-
es emit blue light, which is highly attenuated in living tissue, and
possess high bursting activity, therefore requiring care and pre-
cision in timing the readout. Moreover, their substrate, coelen-
terazine, has been shown to be transported by the multidrug
resistance transporter Pgp (Pichler et al., 2004) as well as to
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Table 1. Common reporter genes for molecular imaging
Imaging modality Reporter gene Mode of action Substrate Reference
Fluorescence imaging Fluorescent proteins Fluorescence None Shaner et al., 2004; Wang et al.,
(GFP, RFP, mPlum, etc.) 2004; Yang et al., 2004; Zhao et 
al., 2001
Bioluminescence Firefly luciferase (FLuc) Enzymatically catalyzed oxidation D luciferin Contag and Ross, 2002;
imaging of substrate to form a light emitting Contag et al., 1997; 
unstable intermediate Contag and Bachmann, 2002
Click beetle luciferases D luciferin Zhao et al., 2004
(CBR, CBG)
Renilla luciferase (RLuc) Coelenterazine Bhaumik and Gambhir, 2001; 
Pichler et al., 2004
Bacterial Lux operon Self-encoded by the C, D, Hardy et al., 2004
and E genes of the Lux
operon
MR imaging and Transferrin receptor (ETR) Selective retention of iron Transferrin-iron oxide Moore et al., 2001; 
spectroscopy Weissleder et al., 2000
yCD Transformation of 5-fluorocytosine 5-FC Stegman et al., 1999
to 5-fluorouracil (5-FU)
Nuclear imaging HSV1-TK Intracellular trapping of [18F]FHBG, [124I]/[131I]FIAU, Doubrovin et al., 2001; Jacobs 
(PET,SPECT) radiolabeled probe by and analogs et al., 2001; Luker et al., 2002b,
phosphorylation Morin et al., 2004
XPRT Intracellular trapping [14C]/[11C]xanthine Doubrovin et al., 2003
SSTR2, D2R Binding of radiolabeled ligand [111In]somatostatin Liang et al., 2002; Rogers et al.,
analogue, [18F]FESP 2000
hNIS Selective retention of [ 124I]/[131I]iodine or Groot-Wassink et al., 2002
radiolabeled probe [99mTc]pertechnetate
CBR/CBG, click beetle red/green luciferase; D2R, dopamine receptor type 2; [18F]FESP, [18F]3-2-(fluoroethyl)spiperone; [18F]FHBG, [18F] 9-[4-fluoro-3-(hydrox-
ymethyl)butyl]guanine; Fluc, firefly luciferase; GFP/RFP, green/red fluorescent protein; hNIS, human Na/I symporter; HSV1-TK, herpes simplex virus-1 thymi-
dine kinase; [124I] or [131I]FIAU, [124I] or [131I]5-iodo-2-fluoro-2deoxy-1-β-D-arabino-furanosyl-uracil; RLuc, Renilla luciferase; SSTR2, Somatostatin receptor type
2; yCD, yeast cytosine deaminase; XPRT, xanthine-phosphoribotransferase.
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interact efficiently with superoxide anion and peroxynitrate in
light-producing reactions (Tarpey et al., 1999), thereby compli-
cating applications of Renilla and Gaussia luciferases in vivo.
As mentioned above, each of the imaging modalities (MR,
nuclear, or optical) has its own strengths and weaknesses (i.e.,
tradeoffs of spatial and temporal resolution, depth of signal
detection, acquisition time, cost, ease of operation, and the
potential for clinical translation) and should therefore be select-
ed primarily according to the examined biological process. This
review is not intended for critical assessment or comparison of
the technical merits of the various modalities, detection devices,
or instruments, and therefore, the reader is referred to recent
comprehensive reviews covering these topics (Bremer et al.,
2003; Contag and Bachmann, 2002; Massoud and Gambhir,
2003; Rudin and Weissleder, 2003; Sharma et al., 2002). No
single modality addresses all aspects of molecular imaging, and
therefore, there is increasing interest in constructing fusion
reporters that combine the positive attributes of different modal-
ities (Doubrovin et al., 2003; Jacobs et al., 2003; Luker et al.,
2002b; Ray et al., 2003, 2004). Herein we will focus on the reg-
ulatory and biochemical elements that govern activation of
imaging reporter genes with an emphasis on cancer, regardless
of their emission characteristics or the imaging modality used to
detect their signal. Different strategies to regulate genetically
encoded reporter activation and thereby detect and dynamical-
ly monitor various components of the cell machinery (transcrip-
tional, posttranscriptional, translational, and posttranslational)
in intact cells and small animal models are summarized in Table
2 and further discussed in the following sections.
Transcriptional regulation of reporter activity
The simplest way to regulate activity of a reporter gene is by
promoter-driven transcription. The earliest applications of
genetically encoded molecular imaging reporters were intended
for studying cell trafficking and engraftment, bacterial or viral
distribution, transgene expression, or analyzing tumor burden
and metastatic activity by expressing reporter genes under the
control of constitutive promoters (e.g., viral promoters such as
pCMV, pSV40, etc.). Typically, cells transfected ex vivo or trans-
duced with engineered viruses enabled reporter monitoring of
spatiotemporal changes in signal after implantation of the cells
or vectors in an intact animal. For example, the ability to monitor
primary tumor burden and response to therapy was studied 
by bioluminescence imaging and crossvalidated by MRI in 
an orthotopically implanted 9L glioma tumor, constitutively
expressing firefly luciferase (Rehemtulla et al., 2000). In this
study, excellent correlation was found between the two imaging
modalities for the kinetics of both tumor growth and drug-
induced cytotoxicity by 1,3-bis (2-chloroethyl)-1-nitrosourea
(BCNU). Historically, in the case of internal orthotopic tumor
models, animal survival was the dominant strategy for monitor-
ing tumor growth and response to therapy prior to small animal
imaging (Contag and Ross, 2002), and thus, imaging strategies
provide more refined readouts of response. While MRI provides
accurate three-dimensional measurements of tumor size, biolu-
minescence imaging of luciferase expression is potentially
superior in reporting the quantity of viable cells.
Monitoring gene delivery and optimizing gene therapy pro-
tocols are other queries for application of simple constitutive
promoters to regulate imaging reporter genes. Constitutive
expression (by an immediate early CMV promoter) of two
reporter genes (D2R and HSV1-TK) within a bicistronic (IRES)
transcriptional unit was used to image adenoviral-mediated
gene delivery by PET imaging for evaluation and optimization of
gene therapy protocols (Liang et al., 2002). It was demonstrated
in this study that the two genes coexpressed primarily in the
liver (the main site for adenoviral infection in mice) over a 3
month period and over a 7- to 10-fold concentration range. In
the case of cancer gene therapy, HSV1-TK is a particularly
attractive reporter gene, since it has the advantage of being
both a therapeutic and a reporter gene (by using ganciclovir
treatment and the appropriate radiolabeled substrate, respec-
tively) (Qiao et al., 2002;Tjuvajev et al., 1999). A variation of this
strategy thereby enabled direct monitoring of inducible suicide
gene therapy for controlling graft versus host disease after allo-
geneic bone marrow transplantation (Rettig et al., 2004).
Tumoral accumulation of HSV-based oncolytic viruses also has
been imaged with an HSV1-TK reporter (Bennett et al., 2001;
Jacobs et al., 2001).
Reporter genes transfected in eukaryotic cells have been
widely used to study cis-regulatory sequences or trans-acting
factors that modulate the transcriptional activity of target pro-
moters. By transducing cells in vivo with an expression cassette
that contains a reporter gene under the control of a transcrip-
tionally regulated sequence, it is now feasible to monitor tran-
scriptional regulation in a living animal. As an example, a
retroviral vector containing the dual reporter gene HSV1-TK-
GFP regulated by an upstream p53 response element
(p53→TK-GFP) was used to transduce U87 glioma (p53+/+) and
SaOS osteosarcoma (p53−/−) cells that were implanted into rats
to establish tumor xenografts (Doubrovin et al., 2001). Whole-
body PET imaging and fluorescence microscopy demonstrated
DNA damage-induced upregulation of TK-GFP in a p53-depen-
dent manner, and this increase in activity correlated with upreg-
ulation of downstream p53-regulated genes as measured by
independent assays.
Anatomical and temporal changes in transcriptional regula-
tion have also been shown to be resolved by reporter gene
imaging in transgenic mouse models. For instance, a transgenic
mouse has been generated wherein firefly luciferase is
expressed under the regulation of an NF-κB response element
and used to study time- and organ-dependent changes in biolu-
minescence after administration of classical stressors such as
tumor necrosis factor α (TNFα), interleukin-1α (IL-1α), or
lipopolysaccharide (LPS), or after inducing genotoxic stress by
UV irradiation (Carlsen et al., 2002). It was demonstrated in this
study that in the absence of extrinsic stimuli, strong NF-kB
activity was evident in cervical lymph nodes, thymus, and
Peyer’s patches. However, treatment with TNFα, IL-1α, or LPS
increased the NF-kB-dependent bioluminescent signal in an
organ-specific manner, with the strongest activity observed in
skin, lungs, spleen, Peyer’s patches, and the wall of the small
intestines. It was further shown that induction of chronic inflam-
mation resembling rheumatoid arthritis produced a strong sig-
nal in affected joints.
To analyze the dynamics of estrogen receptor (ER) tran-
scriptional activity in vivo, a transgenic mouse model was 
generated (Ciana et al., 2003) wherein firefly luciferase is
expressed under transcriptional control of the ER (ERE→FLuc).
As expected, in reproductive organs and in the liver, luciferase
activity paralleled circulating estrogen levels, peaking at
proestrus. However, in non-reproductive organs such as bone
and brain, peak transcriptional activity of estrogen receptors
was observed in diestrus. It was further demonstrated that
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Table 2. Strategies for regulating imaging reporter gene activity
Level of regulation Examined process Strategies Examples References
Transcriptional Transcriptional regulation The promoter of interest drives ERE→FLuc Ciana et al., 2003
the reporter gene
NF-κB→FLuc Carlsen et al., 2002
p53→HSV1-TK-EGFP Doubrovin et al., 2001
AP1→FLuc Huang et al., 1997
Grp78→HSV1-TK Dong et al., 2004
HRE→HSV1-TK-GFP Serganova et al., 2004
Transactivation PSA→ Gal4BD-VP16 + Gal4→FLuc Zhang et al., 2002a
Posttranscriptional RNA splicing Spliceosome-mediated RNA trans-splicing Trans-splicing-mediated Bhaumik et al., 2004
and translational reconstitution of hRLuc mRNA 
Translational regulation Fusing the reporter with a protein that LTR→DHFR-HSV1-TK Mayer-Kuckuk et al., 
regulates its own translation 2002, 2003
Posttranslational Protein-protein interaction Functional complementation of a split CMV→FRB-NFLuc + Luker and Piwnica-
reporter (with or without intein-mediated CMV→CFLuc-FKBP Worms, 2004; Luker et 
reporter reconstitutuion) al., 2004
NF-κB→NFLuc-ID + Paulmurugan et al., 2002
CMV→MyoD-CFLuc
NF-κB→NFLuc-DnaEN-ID + Paulmurugan et al., 2002
CMV→MyoD-DnaEC-CFLuc
Two-hybrid system Gal4BD-p53←TetRE→VP16-TAg + Luker et al., 2002b,
4xGal4→HSV1-TK-EGFP 2003b
Energy transfer (FRET, BRET) CMV→β-arrestin-RLuc + Jares-Erijman and Jovin,
CMV→Ub-GFP 2003; Perroy et al., 2004
Proteasomal degradation N-terminal fusion of tetraubiquitin to CMV→4xUb-FLuc Gross and Piwnica-
(total) the reporter Worms, 2005; Luker et 
al., 2003a
β-actin→4xUb-EGFP Lindsten et al., 2003
Proteasomal degradation Fusion of the substrate of interest to SV40→p27-FLuc Zhang et al., 2004
(substrate-specific) the reporter
CMV→IκBα-FLuc Gross and Piwnica-
Worms, 2004, 2005
CMV→p53-FLuc Rehemtulla et al., 2004
Protease activation Introduction of a protease recognition AMLP→ER-DEVD-FLuc-DEVD-ER Laxman et al., 2002
motif that, when cut, activates the reporter
Nuclear transport Intein-mediated reconstruction of CMV→DnaEC-CRLuc-AR + Kim et al., 2004
nucleocytoplasmic separated CMV→FLAG-NRLuc-DnaEN- NLS
reporter fragments
Cellular Monitoring tumor burden, Constitutive expression of the reporter CMV→FLuc in 9L glioma Rehemtulla et al., 2000
cell trafficking, stem cell gene in the target cells/viruses
engraftment, pathogen 
infection, multidrug resistance
LTR→HSV1-TK in T cells Koehne et al., 2003
UL29→FLuc + UL30→RLuc in HSV Luker et al., 2002a
LTR→FLuc/GFP in αMBP-CD4+ T cells Costa et al., 2001
LP→lux in L. Monocytogenes Hardy et al., 2004
CMV→RLuc Pichler et al., 2004
Combined Conditional organ-specific Cre-loxP recombination β-actin→lox-GFP-lox-FLuc Lyons et al., 2003
reporter expression
ROSA26→lox-stop-lox-FLuc Safran et al., 2003
Spontaneous tumorigenesis Coupling reporter activation with POMC→Cre + POMC→FLuc Vooijs et al., 2002
transformation in a conditional and crossed with a conditional
optionally organ-specific manner lox-Rb-lox knockout
E2F1→FLuc crossed with Nestin→ Uhrbom et al., 2004
tv-a and infected with 
RCAS-PDGFB virus
AMLP, adenoviral major late promoter; AP1, affector protein 1; AR, androgen receptor; Cre, Cre-recombinase; DEVD, asp-glu-val-asp; E2F1, E2F1 promoter; EGFP,
enhanced green fluorescence protein; ERE or ER, estrogen receptor; FKBP, FK506-binding protein type 12; FRB, rapamycin-binding domain of mTOR; Gal4BD,
Gal4 DNA binding domain; Grp78, glucose-regulated protein-78; HRE, hypoxia response element; HSV1-TK, herpes simplex virus-1 thymidine kinase; IκBα, inhibitor
of nuclear factor κB type α; LP, listerial promoter; LTR, long terminal repeat; MBP, myelin binding protein; N/C FLuc, N- or C-terminal fragments of firefly luciferase;
N/C RLuc, N- or C-terminal fragments of Renilla luciferase; NF-κB, nuclear factor κB; N-tv-a, nestin promoter driving TV-a avian virus receptor; NLS, nuclear local-
ization signal; PDGFB, platelet-derived growth factor type B; POMC, lobe-specific pituitary promoter; PSA, prostate-specific antigen; Rb, retinoblastoma tumor
suppressor gene; RCAS, replication-competent avian sarcoma and leucosis virus long terminal splice acceptor; ROSA26, ubiquitous ROSA26 promoter; TAg, simi-
an virus large T antigen; TetRE, tetracycline-responsive element; Ub, ubiquitin; VP16, VP16 transactivator; →, promoter regulation; -, fusion gene; +, coexpression.
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these tissue-specific responses are masked when mice under-
go conventional hormone treatment, and that estrogen recep-
tors are transcriptionally active even in immature mice (before
gonadal production of sex hormones) and in ovariectomized
mice. Overall, this study emphasizes the importance of estro-
gen-independent activation of ER, especially in non-reproduc-
tive organs, and provides far-reaching implications for hormone
replacement therapy and cancer risk.
Imaging posttranscriptional molecular events
Imaging posttranscriptional events, such as translational regu-
lation, protein-protein interactions, protein processing, or pro-
tein degradation, is primarily performed by fusing the reporter
gene, a partial reporter fragment, or an upstream transactivator
to the protein of interest, thereby generating a molecular sensor
that activates (or deactivates) the reporter in response to a
given protein interaction or modification. Fundamentally, the
detection of physical interaction among two or more proteins
can be assisted if association between the interactive partners
leads to the production of a readily observed biological or phys-
ical readout. At present, three general strategies are feasible for
imaging interacting protein pairs in cellulo or in vivo: (1) protein-
protein interaction-dependent reporter gene transactivation or
repression (two hybrid system; recruitment of signal transduc-
tion cascades), (2) reporter complementation, achieved by fus-
ing inactive reporter fragments to interacting proteins, thereby
bringing the fragments into close proximity and restoring
reporter activity (Luker et al., 2004; Paulmurugan et al., 2002,
2004), and (3) energy transfer techniques such as Forster reso-
nance energy transfer (FRET) (Jares-Erijman and Jovin, 2003)
and bioluminescence resonance energy transfer (BRET)
(Perroy et al., 2004). However, energy transfer strategies have
not yet been demonstrated in living animals.
Reporter transactivation
As an example of noninvasive molecular imaging of protein-pro-
tein interactions in vivo by PET and fluorescence imaging, a
fusion reporter gene was engineered comprising a mutant
HSV1-TK and EGFP (mNLS-sr39TK-EGFP) under regulation of
a concatenated Gal4 promoter (Luker et al., 2002b, 2003b).The
p53 tumor suppressor was fused to the Gal4 DNA binding
domain (p53-Gal4BD), and simian virus-associated large T anti-
gen (TAg) was fused to the transactivator VP16 (TAg-VP16).
Expression of p53-Gal4BD and TAg-VP16 was regulated by a
bidirectional, tetracycline-responsive promoter. Thus, upon
treatment with doxycycline, transcription of the reporter gene
was regulated by the known high-affinity interaction between
p53 and TAg. Visualization of the reporter was accomplished
with [18F]FHBG and microPET imaging. Based on region-of-
interest values from the microPET images, the uptake of
[18F]FHBG was 5.5-fold higher than in control xenografts
expressing polyoma virus coat protein fused to VP16 (CP-
VP16) instead of TAg-VP16.
The interaction of two other proteins, ID and MyoD, was
also interrogated in vivo by a similar strategy applied to biolumi-
nescence (Ray et al., 2002). To modulate the expression of
these two proteins, the NF-κB promoter was used to regulate
transcription of the ID-Gal4 and MyoD-VP16 hybrid proteins,
while TNFα was used to induce activation of the NF-κB promot-
er. Firefly luciferase regulated by five repetitive Gal4 elements
was used as the reporter gene.Thus, upon treatment with TNFα
to induce expression of the interacting hybrids, biolumines-
cence was correlated with interaction of ID and MyoD and was
transiently higher than when induced by a noninteracting pro-
tein pair (MyoD and p53).
Reporter fragment complementation and reconstitution
Limitations of transactivation strategies for studying protein-pro-
tein interactions are the requirement for protein translocation
and stable protein interactions in the nucleus, as well as tempo-
ral delays inherent to transcriptional readouts. To circumvent
these limitations, other techniques have been developed. A split
reporter protein approach can be used through either comple-
mentation or reconstitution strategies. Complementation strate-
gies do not require the formation of an intact protein from split
fragments, as opposed to reconstitution strategies that attempt
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Figure 1. Optimization of firefly luciferase
protein-fragment complementation imaging
(LCI)
A: Schematic representation of the optimized
N- and C-terminal fragments of luciferase (as
revealed by screening of incremental trunca-
tion libraries), fused to FRB and FKBP-12,
respectively. 
B: Schematic of LCI. Rapamycin-induced asso-
ciation of proteins FRB and FKBP-12 brings
inactive fragments of luciferase into close
proximity, thereby producing bioluminescence
activity. 
C: Monitoring rapamycin-induced FRB/FKBP12
association in live cells. HEK-293 cells transfect-
ed with FRB-NFLuc + CFLuc-FKBP-12 (upper) or
S2035I FRB-NFLuc + CFLuc-FKBP-12 (lower) were
treated for 6 hr with 50 nM rapamycin. Note
that the S2035I mutation of mTOR/FRB is known
to abrogate the rapamycin-induced associa-
tion of FRB and FKBP-12. A pseudocolor IVIS
bioluminescence image of live cells in a 96-
well plate is shown. 
D: Luciferase complementation imaging of
two representative nu/nu mice, one implanted
with HEK-293 cells expressing FRB-NFLuc +
CFLuc-FKBP (upper) and the other with cells
expressing mutant S2035I FRB-NFLuc + CFLuc-FKBP-12 (lower). Images were taken 18 hr before treatment with rapamycin (left) and 2.5 hr after receiving
a single dose of rapamycin (4.5 mg/kg, i.p., right).
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to reconstitute the mature reporter protein. Reporter comple-
mentation is based on the principle that reporter activity (e.g.,
enzymatic activity) is regained when its split fragments are
brought into close proximity due to a specific protein-protein
interaction. Protein-protein interactions can also drive reporter
reconstitution by intein-mediated protein autosplicing.
The interaction of ID and MyoD was demonstrated in vitro
and in vivo by firefly luciferase complementation and reconstitu-
tion (Paulmurugan et al., 2002). However, in this study, firefly
luciferase fragments suffered from constitutive activity of the N-
terminal fragment. Reporter complementation was also demon-
strated using Renilla luciferase split fragments (Kim et al., 2004;
Paulmurugan and Gambhir, 2003; Paulmurugan et al., 2004),
though the blue-green emission spectrum of Renilla luciferase
penetrates tissues poorly, thereby precluding general use.
Furthermore, coelenterazine, the bioluminescent substrate for
Renilla luciferase, was shown to be transported by the multidrug
resistance transporter Pgp (see Pichler et al., 2004, and below),
complicating applications of Renilla luciferase in vivo.
Consequently, to facilitate the study of regulated protein-protein
interactions in cells and living animals, an optimized firefly
luciferase protein fragment complementation system was devel-
oped by screening incremental truncation libraries of N- and C-
terminal fragments of firefly luciferase. The initial seeds for the
screen were inactive firefly luciferase fragments fused to the
rapamycin binding domain (FRB) of the kinase mammalian target
of rapamycin (mTOR) and FK506 binding protein 12 (FKBP),
respectively (Luker and Piwnica-Worms, 2004; Luker et al.,
2004). The optimized FRB-NLuc/CLuc-FKBP pair (containing
2–416 N-terminal and 398–550 C-terminal overlapping luciferase
fragments; Figure 1A) generated luciferase activity in cells upon
single-site binding of rapamycin in an FK506-competitive manner
(Figure 1B).The inducibility range of optimized luciferase comple-
mentation imaging (LCI) was robust, with drug-specific induction
of bioluminescence reaching 1,200-fold over background,
exceeding currently available systems (Figures 1C and 1D). This
property enabled monitoring of lower affinity protein-protein inter-
actions, such as homodimerization of nonphosphorylated STAT1
and the phosphorylation-dependent interaction between human
Cdc25C with 14-3-3ε in vivo (Luker et al., 2004).
Imaging total- and substrate-specific proteasomal 
degradation
The ubiquitin-proteasome pathway is the central mediator of reg-
ulated proteolysis, an instrumental switch for a variety of signal-
ing cascades. Deregulation of proteasomal activity or improper
substrate recognition and processing by the ubiquitin-protea-
some machinery may lead to cancer, stroke, chronic inflam-
mation, and neurodegenerative diseases. To monitor total
proteasomal activity, an ubiquitin-luciferase bioluminescence
imaging reporter was developed by fusing the N terminus of fire-
fly luciferase to four copies of a mutant ubiquitin (UbG76V, Figure
2A, upper panel) (Luker et al., 2003a). The tetraubiquitin fusion
degradation motif has been shown to significantly destabilize
heterologous proteins in cultured cells (Stack et al., 2000), while
the glycine to valine substitution at the C terminus of ubiquitin
limits cleavage by ubiquitin hydrolases (Johnson et al., 1992;
Stack et al., 2000). Both in cultured cells and in tumor xenografts,
the 4xUb-FLuc reporter was degraded rapidly under steady-
state conditions and stabilized in a concentration- and time-
dependent manner in response to various proteasome inhibitors
(Figure 2A, lower panel). Bioluminescence imaging revealed that
proteasome function in tumor xenografts was blocked as soon
as 30 min after administration of a single dose of the chemother-
apeutic proteasome inhibitor bortezomib and returned to nearly
baseline by 46 hr. However, after a two-week regimen of borte-
zomib, imaging of target tumors showed significantly enhanced
proteasome inhibition that no longer returned to baseline.
Similar to 4xUb-FLuc for imaging total proteasome activity,
fusing a proteasomal substrate to the N terminus of FLuc gen-
erates a reporter responsive to degradation of that specific pro-
teasomal substrate. For example, it was recently demonstrated
that bioluminescence imaging of inhibitor of κB (IκBα)-specific
proteasomal degradation using an IκBα-FLuc fusion reporter
can monitor in real time nuclear factor-κB (NF-κB) activation
and pharmacological modulation (Gross and Piwnica-Worms,
2004, 2005), independent of transcriptional or translational
events. Reporter degradation was monitored both in cultured
cells after treatment with tumor necrosis factor (TNFα) and in
response to treatment with lipopolysaccharide (LPS) in vivo
using a liver inflammation model, wherein the IκBα-FLuc
R E V I E W
Figure 2. Imaging total- and substrate-specific proteasome activity
A: In vivo bioluminescence imaging of Ub-FLuc monitors total proteasome function and inhibition in living mice. Upper panel: schematic of the Ub-FLuc
reporter. Lower panel: mice bearing size-matched tumors were imaged one day before (−) and four hours after tail vein injection of the indicated doses of
bortezomib. Unfused FLuc, Ub-FLuc, and vector control tumors are denoted by black arrows, yellow arrows, and asterisks, respectively. 
B: Real-time bioluminescence imaging of IκBα-specific proteasomal degradation in a somatic gene transfer mouse model. Upper panel: schematic of the
IκBα-FLuc reporter. Lower panel: representative bioluminescence images of RLuc (left two panels) and IκBα-FLuc (right two panels) taken before or 1 hr after
induction of acute liver inflammation by intravenous injection of LPS (4 µg/g BW). All images correspond to an individual mouse. Note that plasmids encod-
ing RLuc and IκBα-FLuc were delivered to the liver by high-volume intravenous injection.
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reporter was delivered to liver hepatocytes by hydrodynamic
somatic gene transfer (Figure 2B). Moreover, pretreatment with
proteasome inhibitors or inhibitors of IκB-kinase (IKK) was
shown to abrogate ligand-induced reporter degradation.
A similar strategy was used to monitor cell cycle-regulated
degradation of the cyclin-dependent kinase 2 (cdk2) inhibitor
p27 using a p27-FLuc fusion reporter (Zhang et al., 2004). It
was shown in this study that reporter activity is regulated by its
E3-ligase Skp2 in a cell cycle-dependent manner. Blockade of
cdk2 activity by drugs, inhibitory proteins, peptides, or small
interfering RNA (siRNA) induced reporter accumulation and
increases in bioluminescence. Elevation in reporter activity due
to pharmacological modulation of cdk2 was also documented in
vivo in human tumor xenografts.
Imaging caspase-3 activation
The cysteine protease caspase-3 is an effector caspase acti-
vated during apoptotic cell death by upstream initiator cas-
pases (i.e., caspases 8, 9, 10, and 12). Once activated,
caspase-3 executes apoptosis by cleaving cellular proteins at
a specific DEVD consensus motif. To enable noninvasive and
repetitive imaging of apoptosis in living animals, a reporter
was engineered (Laxman et al., 2002) for bioluminescence
imaging wherein the estrogen receptor regulatory domain
(ER) was fused to FLuc, thereby sterically silencing FLuc cat-
alytic activity. Inclusion of a DEVD sequence between these
two moieties allowed for caspase-3-mediated restoration of
luciferase activity, enabling real-time monitoring of apoptotic
activation. Using this reporter, the investigators demonstrated
activation of caspase-3 in intact cells and living animals in
response to treatment with TNFα-related apoptosis-inducing
ligand (TRAIL). Furthermore, ZVAD-fmk, a general caspase
inhibitor, was shown to abrogate TRAIL-induced reporter acti-
vation, thus confirming the role of caspases for regulating
activity of this reporter.
Imaging multidrug resistance
Coelenterazine, the bioluminescent substrate of the reporter
gene Renilla luciferase, is a substrate for the multidrug trans-
porter Pgp (Pichler et al., 2004). In cultured living cells, stably
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Table 3. Examples of transgenic mouse models expressing reporter genes suitable for molecular imaging applications
Reporter gene Activity Transgene References
Firefly luciferase AP-1-dependent transcription AP-1→FLuc Huang et al., 1997
NF-κB-dependent transcription κB→FLuc Carlsen et al., 2002
Activation of estrogen receptor (ER) ERE→FLuc Ciana et al., 2003
Circadian gene expression mPer1→FLuc Wilsbacher et al., 2002
Neuronal damage GFAP→FLuc Zhu et al., 2004
Drug metabolism CYP3A4→FLuc Zhang et al., 2003
Bilirubin synthesis HO1→FLuc Zhang et al., 2002b
Bone repair and development hOC→FLuc Iris et al., 2003
Cre-mediated activation β-actin →lox-GFP-lox-FLuc; Lyons et al., 2003; 
ROSA26→lox-stop-lox-FLuc Safran et al., 2003
E2F1-dependent transcription E2F1→FLuc Uhrbom et al., 2004
Pituitary spontaneous tumorigenesis POMC→Cre + POMC→Fluc Vooijs et al., 2002
Angiogenesis VEGFR2→FLuc Zhang et al., 2004
Fluorescent proteins Neuronal development nestin→GFP Yamaguchi et al., 2000
Embyonic germ cell migration Oct4→GFP Anderson et al., 2000
Ureteric bud development Hoxb7→GFP Srinivas et al., 1999
Angiogenesis VEGF→GFP Fukumura et al., 1998
Lymphocyte development Gfi1→GFP Yucel et al., 2004
X chromosome inactivation CMV→GFP in X chromosome Hadjantonakis et al., 2003
Synaptic formation and plasticity Thy1→GFP, Thy1→YFP, Feng et al., 2000; Sakai et al., 2004; 
Thy1→CFP, TetRE→PKCγ-GFP Trachtenberg et al., 2002
Proteasome activity β-actin→Ub-GFP Lindsten et al., 2003
Embryonic perfusion ε-globin→GFP Jones et al., 2002
Ubiquitous GFP expression β-actin→GFP Yang et al., 2004
HSV1-TK Endothelial damage VE-cad→HSV1-TK Dancer et al., 2003
Liver targeting Alb→Cre + CAG→lox-stop-lox- Sundaresan et al., 2004
HSV1-TK adenovirus
Germ cell ablation Inhα→HSV1-TK Ahtiainen et al., 2004
GVH disease control CD2→∆CD34-HSV1-TK Rettig et al., 2004
Alb, albumin promoter; AP1, affector protein 1; CAG, cytomegalovirus immediate early gene 1 enhancer; CD2, T cell locus promoter; CFP, cyan fluorescent
protein; CMV, cytomegalovirus promoter; CYP3A4, cytochrome P450-3A promoter; Cre, Cre-recombinase; E2F1, E2F1 promoter; ERE, estrogen receptor;
FLuc, firefly luciferase; GFAP, glial fibrillary acidic protein promoter; Gfi1, growth factor independence promoter; GFP, green fluorescent protein; GVH, graft
versus host; HO1, heme-oxygenase 1; hOC, human osteocalcin promoter; Hoxb7, homeobox B7 promoter; HSV1-TK, herpes simplex virus-1 thymidine kinase;
Inhα, inhibin-alpha promoter; κB, κB response element; mPer1, mammalian period-1 promoter; Oct4, POU5F1 promoter; PKCγ, protein kinase Cγ; POMC,
lobe-specific pituitary promoter; TetRE, tetracycline-responsive element; Thy-1, a mature neuronal marker promoter; Ub, ubiquitin; VE-cad, vascular
endothelial cadherin promoter; VEGF, vascular endothelial growth factor promoter; VEGFR2, VEGF receptor type 2 promoter; YFP, yellow fluorescent pro-
tein; →, promoter regulation; −, fusion gene; +, coexpression.
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transfected with a codon-humanized Renilla luciferase, it was
shown that low baseline coelenterazine-mediated biolumines-
cence could be fully enhanced (reversed) to non-Pgp matched
control levels with potent and selective Pgp inhibitors.
Therefore, using coelenterazine and noninvasive biolumines-
cence imaging in vivo, tumor-specific Pgp transport activity and
inhibition could be monitored in living mice. This study empha-
sizes the role of coelenterazine as a Pgp substrate, but at the
same time raises concerns regarding the indiscriminative use of
Renilla luciferase and aequorin as reporters in intact cells and
transgenic animals, since Pgp-mediated alterations in coelen-
terazine permeability may impact results.
Imaging oncogenic transformation and spontaneous
tumorigenesis
The use of transgenic animal models of human diseases
promises to extend our understanding of the mechanisms of
pathogenesis by placing target genes and processes in the
appropriate physiological milieu. However, until recently,
analysis of these animal models was limited by the ability to
monitor only obvious phenotypic changes or perform destruc-
tive analyses at defined time points. In cancer research, this
pitfall becomes a major drawback, because almost all aspects
of tumorigenesis, tumor growth, invasion, metastatic potential,
and response to therapy are dynamic in time and space.
Moreover, while it is clear that the closest approximation of
human cancers is attained by spontaneous transformation
models, the stochastic nature of spontaneous tumors compli-
cates and thereby severely limits the application of these mod-
els. Consequently, recent advances in small animal imaging
instrumentation, molecular genetics, and reporter gene
design have yielded the ability to integrate an imagable
reporter capacity into transgenic models of human diseases.
Such aptitude not only refines the data by allowing each ani-
mal to serve as its own control, but also permits in vivo high-
throughput analyses of drugs for preclinical trials. Consecutive
analysis of the same animal means that fewer animals are
needed for each study and experimental uncertainties arising
from inter-animal variations are greatly reduced (Herschman,
2003). Table 3 provides detailed information on available
transgenic mouse models expressing
such imagable reporters.
Of particular interest is a transgenic
mouse model (Vooijs et al., 2002) wherein
both firefly luciferase and Cre recombi-
nase were expressed solely in the pitu-
itary gland under the control of the
intermediate lobe-specific POMC promoter. These mice were
crossed with mice carrying conditional lox-Rb-lox alleles, thereby
coupling luciferase activation to deletion of Rb and development
of pituitary-specific melanotrophic tumors. This sophisticated
model allowed the researchers to monitor, by bioluminescence
imaging, tumor onset, progression, and response to antineoplas-
tic therapy, thereby generating temporally resolved, statistically
significant data from a relatively small cohort of animals.
There is no doubt that conditional activation or deletion of
an oncogene or a tumor suppressor gene, coupled with reporter
gene expression (e.g., by using Cre/loxP conditional recombi-
nation technology) is indispensable for longitudal studies of the
role of a specific transformation event for tumorigenesis.
However, to limit the need to generate, optimize, and validate
novel independent transgenic luciferase mouse strains for each
conditional transformation model, a ubiquitously expressing
conditional luciferase reporter mouse was developed that can
be used to render a wide range of Cre/loxP mouse tumor mod-
els for bioluminescence imaging (Lyons et al., 2003). Herein, a
β-actin promoter drives FLuc in a Cre-dependent manner. To
illustrate the usefulness of this model, the investigators coupled
luciferase activation with lung tumorigenesis, induced by
Kras2v12 (a constitutively active ras mutant) in a preexisting
mouse model of non-small cell lung cancer, and followed onset
and progression of the spontaneously generated lung tumors.
An improved version of a conditional loxP-luciferase mouse was
recently described (Safran et al., 2003), where a true knockin
was generated by introducing a lox-stop-lox cassette upstream
to firefly luciferase cDNA under the control of the ubiquitous
ROSA26 promoter. Another advantage of this model over previ-
ous attempts (Lyons et al., 2003) is the use of codon-optimized
firefly luciferase, thereby increasing its activity by two orders of
magnitude.
In the studies mentioned above (Lyons et al., 2003;Vooijs et
al., 2002), luciferase activation was regionally coupled to Cre-
mediated Rb knockout (Vooijs et al., 2002) or Cre-mediated
Kras2v12 expression (Lyons et al., 2003), but not biochemically
dependent on the molecular transformation event; i.e.,
luciferase did not serve as a downstream target reporter of Rb
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Figure 3. Imaging tumor burden and response to
therapy in spontaneous glioma tumorigenesis
modal
A: Generation of Ef-FLuc + N-tv-a double trans-
genic mice (see text for further details). 
B: Approximate correlation between BLI output
and tumor size. Upper panel: luciferase activity
in tumor-bearing Ef-FLuc + N-tv-a transgenic
mice. Lower panel: Whole-mount histologic
analysis of the brains from the same mice as
imaged in the upper panel. Note that tumor size
correlates with the amount of emitted light. 
C: Longitudinal imaging of one tumor-bearing
mouse treated with the PDGFR inhibitor
PTK787/ZK222584 daily for 6 days. NT, biolumi-
nescence before drug treatment. Modified
from Uhrbom et al. (2004) with permission from
Nature Medicine (http://www.nature.com/nm).
CANCER CELL : JANUARY 2005 13
or K-ras function in Vooijs et al. (2002) and Lyons et al. (2003),
respectively. In contrast, a recent transgenic mouse model to
study gliomagenesis by bioluminescence imaging was reported
(Uhrbom et al., 2004), wherein luciferase activation is not only
coupled, but also dependent upon platelet-derived growth factor
(PDGF)-induced loss of Rb. This mouse (Ef-FLuc) expresses
luciferase under the control of the E2F1 promoter, which is neg-
atively regulated by Rb under normal conditions, and thus
luciferase activity increases upon loss of Rb in tumors, regard-
less of mitotic status.These mice were crossed with N-tv-a mice
that express the viral receptor tv-a from the nestin promoter,
thereby restricting retroviral transactivation of E2F1→FLuc to
glial progenitor cells using viral PDGF-RCAS vectors (Figure
3A) (Holland, 2001).This strategy enables spontaneous glioma-
genesis and tumor progression to be followed noninvasively
and repetitively over time (Figure 3B). Furthermore, the biolumi-
nescent signal correlates in this model to both tumor cell num-
ber and loss of Rb control, thereby enabling analyses of the
potency and pharmacodynamics of drugs that interfere with
tumor maintenance and proliferation (i.e., PDGFR and mTOR
inhibitors) as well as cytotoxic drugs (see Figure 3C for a
PDGFR inhibitor).
Concluding remarks
Integration of genetically encoded imaging reporters into intact
cells and small animal models of disease has provided powerful
tools to monitor cancer-associated molecular, biochemical, and
cellular pathways in vivo. These types of studies are gaining
widespread acceptance within the scientific community and
therefore could be considered in some cases to be the method
of choice for deciphering complex biological responses in a liv-
ing animal. We predict that more researchers will continue to
take advantage of these new capabilities, thus allowing them to
noninvasively “spy” on cancer-specific molecular and regulatory
cascades in the intact animal.
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